nct_id: NCT05927857
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-07-03'
study_start_date: '2024-04-01'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Trifluridine/Tipiracil /Experimental'
  - drug_name: 'Drug: Ramucirumab /Experimental'
  - drug_name: 'Drug: nal-IRI /Experimental'
long_title: "A Phase Ib/II Study of Ramucirumab (Cyramza\xAE), Nal-IRI (ONIVYDE\xAE\
  ) and Trifluridine/Tipiracil (Lonsurf\xAE) in Second Line Metastatic Gastric Cancer\
  \ (COOL Study)."
last_updated: '2025-08-22'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: Nai-Jung Chiang, MD-PhD
principal_investigator_institution: National Health Research Institutes, Taiwan
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 45
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. histologically or cytologically confirmed metastatic gastric adenocarcinoma
- 2. patients have received only first line of systemic therapy, including recurrence
  during adjuvant therapy or within 6 months after the completion of adjuvant treatment.
- 3. ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1
- 4. patients with HER2/neu-positive tumor must be exposure to Herceptin treatment
- 5. at least one measurable disease according to the RECIST version 1.1;
- 6. patients are aged 20 to 80 years;
- "7. patients have a life expectancy \u2265 3 months;"
- "8. patients have adequate renal function with defined as serum creatinine \u2264\
  \ 1.5 times the upper limit of normal (ULN) or Ccr \u2265 40 mL/min;"
- "9. patients with adequate hepatic function as defined by a total bilirubin \u2264\
  1.5 times the ULN, and aspartate transaminase (AST) and alanine transaminase (ALT)\
  \ \u2264 3 times the ULN or 5 times the ULN in the setting of liver metastases."
- "10. patients have adequate bone marrow function, defined as an absolute neutrophil\
  \ count \u2265 1500/mm3, hemoglobin \u22659 g/dL, and platelet count \u2265 100,000/mm3\
  \ (transfusion or G-CSF support before enrollment is allowed)"
- "11. patients have International Normalized Ratio (INR) \u22641.5 and a partial\
  \ thromboplastin time (PTT) (PTT/aPTT) \\< 1.5 x ULN;"
- "12. patients' urinary protein is \u22641+ on dipstick or routine urinalysis or\
  \ a 24-hour urine collection for protein must demonstrate \\<1000 mg of protein\
  \ if urine dipstick or routine analysis is \u2265 2+;"
- 13. patients with childbearing potential shall have effective contraception for
  both the patient and his or her partner during the study;
- 14. female patients of childbearing potential must have a negative serum pregnancy
  test within 7 days prior to first dose of protocol therapy;
- 15. the ability to understand and willingness and to sign a written informed consent
  document.
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. patient can't take oral drugs;
- Exclude - 2. known hypersensitivity to irinotecan, fluoropyrimidine, or ramucirumab;
- Exclude - 3. receipt of surgery within the past 4 weeks before study enrollment;
- "Exclude - 4. \u2265 grade 2 diarrhea and ascites"
- Exclude - 5. concurrent severe infection with intravenous systemic antibiotics treatment;
- Exclude - 6. patients have experienced any arterial thromboembolic events, including
  but not limited to myocardial infarction, transient ischemic attack, cerebrovascular
  accident, or unstable angina, within 6 months prior to first dose of protocol therapy;
- Exclude - 7. patients have a prior history of GI perforation/fistula (within 6 months
  of first dose of protocol therapy) or risk factors for perforation;
- 'Exclude - 8. patients have:'
- Exclude - * cirrhosis at a level of Child-Pugh B (or worse) or
- Exclude - * cirrhosis (any degree) and a history of hepatic encephalopathy or clinically
  meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined
  as ascites from cirrhosis requiring diuretics or paracentesis;
- Exclude - 9. patients have a serious or nonhealing wound, ulcer, or bone fracture
  within 28 days prior to first dose of protocol therapy;
- Exclude - 10. patients have undergone major surgery within 28 days prior to first
  dose of protocol therapy, or minor surgery/subcutaneous venous access device placement
  within 7 days prior to the first dose of protocol therapy. Patients have elective
  or planned major surgery to be performed during the course of the clinical trial;
- Exclude - 11. patients have uncontrolled or poorly-controlled hypertension (\>160
  mmHg systolic or \> 100 mmHg diastolic for \>4 weeks) despite standard medical management;
- Exclude - 12. patients have experienced any grade 3-4 GI bleeding within 3 months
  prior to first dose of protocol therapy;
- Exclude - 13. patients have a history of deep vein thrombosis (DVT), pulmonary embolism
  (PE), or any other significant thromboembolism (venous port or catheter thrombosis
  or superficial venous thrombosis are not considered "significant") during the 3
  months prior to first dose of protocol therapy;
- Exclude - 14. patients are receiving chronic antiplatelet therapy, including dipyridamole
  or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day)
  is permitted;
- "Exclude - 15. previously received prior nal-IRI (ONIVYDE\xAE) or TAS-102 (LONSURF\xAE\
  ) or ramucirumab therapy"
- Exclude - 16. another previous malignancy diagnosed within the past 5 years except
  for non melanoma skin cancer or stage I cervical cancer;
- Exclude - 17. pregnant or breast feeding women.
short_title: Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf)
  in Second Line Metastatic Gastric Cancer .
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: National Health Research Institutes, Taiwan
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "Primary Objectives\n\n* In phase 1b cohort, to determine MTD (maximum tolerated\
  \ dose) of nal-IRI (ONIVYDE\xAE) in combination with Ramucirumab (Cyramza\xAE) and\
  \ TAS-102 (LONSURF\xAE)\n* In phase II cohort, to evaluate disease objective response\
  \ rate (ORR) of Ramucirumab (Cyramza\xAE), nal-IRI (ONIVYDE\xAE) in combination\
  \ with TAS-102 (LONSURF\xAE) Secondary Objectives\n* To evaluate disease control\
  \ rate (DCR)\n* To evaluate progression-free survival (PFS)\n* To evaluate overall\
  \ survival (OS)\n* To assess the safety profile\n* To study the blood biomarkers"
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Phase 1b/II
      arm_internal_id: 0
      arm_description: '* Infusional nal-IRI (ONIVYDE, free form) 50/60/70 mg/m2 over
        90 minutes day 1.

        * Infusional Ramucirumab(Cyramza)8 mg/kg over 60 minutes day 1.

        * oral Trifluridine/Tipiracil TAS-102 (LONSURF) 30 mg/m2/b.i.d. day 1-5.

        * Every 14 days count as one cycle.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: nal-IRI /Experimental'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Ramucirumab /Experimental'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Trifluridine/Tipiracil /Experimental'
        level_internal_id: 2
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=20'
        her2_status: Positive
        disease_status:
        - Metastatic
        - Recurrent
        oncotree_primary_diagnosis: Esophagogastric Adenocarcinoma
